HOLDING STRONG!
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Thanks sharkey.
I tired to link it directly Elite's page but I see now the link doesn't work. Appreciate the help for the board.
Your link does. I search the same way.
Opiate analgesics next? $720 million So based on info provided by Winechemist's excellent guidance GUDUFA target date assigned, from his experience this is running 9-12 months out. We know Elite filed an Abbreviated New Drug Application (ANDA) on August 17, 2023, and was accepted for review by the US Food and Drug Administration (FDA) on September 19, 2023 for an undisclosed generic drug product in a class of medications called opiate analgesics. IQVIA reported annual sales for the twelve months ending June 2023 of $720 million for the brand and generic market for this product.
FDA approval could come as soon as JUNE/JULY this summer.... or later OCT/NOV but we are seeing that ELITE has a pattern of getting approvals.
Just gets better and better and will go higher and higher!!!
NAS, yes you are correct, that was global.
From Elite's PR on FDA acceptance - $42 million
April 20, 2023 / Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB:ELTP), a specialty pharmaceutical company developing niche generic products, today announced that it filed an Abbreviated New Drug Application (ANDA) with the US Food and Drug Administration (FDA) for an undisclosed generic drug product in a class of medications called antimetabolites. IQVIA reported annual sales for the twelve months ending December 2022 of $42 million for the generic market for this product.
Methotrexate Sodium Market was US$ 95 million in 2023 and is expected to reach US$ 141.7 million by 2030, at a CAGR of 5.8% during the years 2024
ELTP's FDA Orange Book link -
https://www.accessdata.fda.gov/scripts/cder/ob/search_product.cfm
Click on the "Appl. No." twice and it will sort from most recent to oldest approvals.
METHOTREXATE SODIUM comes to the top when you sort the application number twice.
Its Elite - ELTP - straight from the FDA Orange Book -
Active Ingredient: METHOTREXATE SODIUM
Proprietary Name: METHOTREXATE SODIUM
Dosage Form; Route of Administration: TABLET; ORAL
Strength: EQ 2.5MG BASE
Reference Listed Drug: No
Reference Standard: No
TE Code: AB
Application Number: A216453
Product Number: 001
Approval Date: May 16, 2024
Applicant Holder Full Name: ELITE LABORATORIES INC
Marketing Status: Prescription
Patent and Exclusivity Information
LOL!!! The entire stock market is "what if".
Go find your own income projection and share with the board.
Do your DD, generate your own estimate of potential income and see if Elite beats it.
What is your objective here? Why are you always trying to pick an argument? Why are you always a negative nelly?
I gave you info/data so do your own research and give the boards some FACTS to refute any speculation of improvements in Elite's income potential. Bet you can't, bet the entire board knows your response already, lol.
A little more help with just two minutes of looking -
https://www.investors.com/news/technology/teva-stock-what-we-know-and-do-not-about-the-adderall-shortage/
In 2021, the latest year for which there are data, almost 1.9 billion branded and generic Adderall pills were distributed in the U.S., according to Symphony Health. Teva distributed most of those, at 565 million. At the lowest generic price of 26 cents a pill, that would come to $146.9 million in sales. That doesn't account for the cut drug wholesalers would take of that 26 cents, however. And that's only U.S. sales.
Teva Stock: Sales Likely Higher
Teva's sales are likely higher than that, though, says Joey Mattingly, an associate professor and vice chair for research at the University of Utah's Department of Pharmacotherapy. Brand-name Adderall costs more per pill than its generic counterparts.
Publicly available data shows Veterans Affairs pays $2.61 a pill for the extended-release version of Adderall from Takeda. The agency pays $5.81 per pill for the immediate-release formula from Teva.
"The branded cost is a magnitude higher," Mattingly said in an interview, "15 to 20 times higher."
In December 2022, brand-name Adderall accounted for 17% of prescriptions, according to Iqvia. If that percentage is consistent at Teva, about 96 million of the pills Teva dispensed in 2021 were for the branded version of Adderall, with the remainder being generic. That would come out to nearly $680 million in sales.
Here is a little help to get you started -
Cincinnati, OH, June 28, 2016/PRNewswire/ — Prasco Laboratories (“Prasco”) today announced that it has entered into agreements with Teva Pharmaceutical Industries Ltd. (Teva) and Shire LLC, an indirect subsidiary of Shire plc, to acquire the rights to distribute Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate and Amphetamine Sulfate (Mixed Salts of a Single-Entity Amphetamine Product) Extended Release Capsules, CII, 5 mg, 10 mg, 15 mg, 20 mg, 25 mg, and 30 mg, the Authorized Generic (AG) version of Adderall XR® Extended Release Capsules, CII.
So look for how much Teva was making off of their generic adderall xr from 2016 to 2022 and see if you can get an idea of how much Elite can get.
Do your own due diligence.... Prasco was the distribution and marketing for Teva's Adderall XR so dig into internet research and see if you can determine market share. PROBABLY HUGE!!!
Also, great link for those that seek the truth....
LOL, everybody! Longs, shorts, the goat crowd....
ELTP shares are getting harder to buy sooner than I thought. Looks like ELTP LONG shareholders are holding on to their shares like Warren Buffett the Oracle of Omaha! Why? Because holding stocks according to some mechanical metric, buy and hold works!!! We are about 40 days away from Elite's report of financial results and ELTP shares will get even harder to acquire at lower PPS. Elite long shareholders are not looking at the end of June or even the end of 2024 - they are looking at a buyout at a PPS much much greater than today's. Sure there will be flippers in July but everyone knows with increasing revenue and gamechanger approvals possible in the near future - the buy as much as possible and HOLD for the big profit WORKS!!!
Based on previous years, I expect Elite Pharmaceuticals to report financial results for fiscal year that ended March 31, 2024 on June 27, 2024.
Right now we have some hoping it will drop more and are afraid to buy because it might go down half a penny, lol. Then we have some that are buying now because they have funds that became available and they know it really isn't gonna matter that much when it starts to climb higher. Will we see another $0.15 rise or even more?? What if ELTP gets an approval between now and then?? A big approval?? What if Generic Adderall XR distribution and marketing partner Prasco provides much more income than we all expected (full quarter and ELTP gained huge market with their initial generic adderall start)??
So much to think about and trying to time buys for a penny less is ridiculous, lol... YOLO-Get on the boat now or get left at the pier!!!
Preventing brokers from loaning your ELTP shares and start thinking about how to fight back....
GME traders are gearing up to take out the shorts (especially those that are naked). Search the boards for Roaring Kitty DFV and read about what they are working on to battle the street and the worst of the short traders.
Understanding Direct Registration
If an issuer offers direct registration for its securities, you can choose to be registered directly on the books of the issuer (maintained by its transfer agent) even if you bought your securities through a broker-dealer.
Direct registration allows you to have your securities registered in your name—rather than in the name of a brokerage firm—without the need for a physical certificate, which could be lost or stolen, to serve as evidence of your ownership. While you won’t receive a certificate, you will receive transaction advice detailing any transactions, as well as periodic account statements, dividends, annual reports, proxies and other communications directly from the issuer or its transfer agent.
Issuers or transfer agents typically don’t charge fees for direct registration. However, you might be charged for transferring securities from one form of ownership to another. Always ask your broker-dealer and the issuer about potential costs if you’re considering transferring securities to a different form of ownership, such as from street name to direct registration.
Here are some factors to keep in mind if you’re considering buying or selling direct registered securities:
Purchases:
Purchases made through the issuer (or its transfer agent) of securities you intend to hold in direct registration are usually executed under the guidelines of the issuer’s stock purchase plan. You’ll need to instruct the transfer agent to move the securities to the DRS.
Issuers’ transfer agents typically don’t maintain cash accounts for investors. When you make a purchase, you’ll need to send the transfer agent the necessary funds.
Purchases through issuer plans are typically processed on a “batch processing” basis, so there may be a time lag before the order is executed. In rapidly changing markets, this could result in receiving a different price than you intended.
PPS is not going much of anywhere until JUNE 27, 2024 unless manipulated down more OR we get news of a FDA approval... until then we just watch the circus animals!
I do expect an earnings surprise to the UP side when ELTP shares their annual report at the end of JUNE.
I was reading a stack and immediately thought of ELTP when reading the below.
-removed company names and replaced with Xs, insert ELTP where appropriate and any other pharma where appropriate : )
Remember XXXXX also was heavily shorted, and their stock went basically flat until they ramped up production. Shot up pretty fast once the shorts got pushed out. The longer the base the bigger the breakout. XXXXX didn't have a pr department. They just said watch us work and they pushed out xxxxx being outsold by their product worldwide.
Who else has been quiet working and not giving out any guidance. But instead went from negative earnings to positive.. the longer they keep XXXXXXX down the harder its going to rocket. They can't ignore a profitable company with billions in their war chest. XXX much like XXXXX will have its day in the sun soon.
Can you short OTC stocks?
This question has an interesting answer. Yes, you technically can short Over the Counter stocks in that there is no law forbidding you from doing so. The problem with this comes from the mechanism of shorting itself. Typically you need to borrow these shares from a brokerage to start your short sell. Well, most brokerages will not have the liquidity in the Over the Counter stock to even allow short selling.
With lower liquidity for the stocks, it is definitely easier to manipulate the price action on the OTC markets. This means that short sellers can take advantage of this and potentially initiate a short sell that could decimate the OTC stock. Because of this, there are some brokerages that will forbid you from short selling an Over the Counter stock.
https://www.tradingsim.com/blog/over-the-counter-otc-stock-trading-explained-tradingsim
So, YES, OTC stocks can be shorted. It is legal! Now, having the money and connections to short is the key. In the USA or off-shore, someone is in a huge coordinated effort to drive ELTP down, but who???
Or, is it the short term traders dumping for a profit as they know there will be no more reports until JUNE 2024 when Elite releases the Annual Report. We may here news of an ANDA approval but FDA is not in as big of a hurry as they were a few years ago.
IMHO, at some point this year 2024, the market will correct for ELTP and all those on the wrong side (short) will LOSE hugely!!!
The Empty Adderall Factory A drugmaker’s feud with the DEA is exacerbating the ADHD meds crisis — at a rate of 600 million missing doses a year.
https://nymag.com/intelligencer/article/adderall-shortage-adhd-medication-ascent-pharmaceuticals.html
SIX decimal places for ELTP AGAIN! Yep, no manipulation, LOL! MMs have been hitting ELTP hard for the past few trading days but if you have been watching... when they are using six decimal places repetitively, ELTP ends up going up!!! We have seen this from $0.03 all the way up to $0.20 so is $0.40 or $0.60 the next leg up???
USA Today - ADHD drug prices rise as Adderall shortage leaves patients scrimping to fill prescriptions
Google it - great for ELTP especially with new partner for XR!
The upward trend can be seen in the prices retail community pharmacies pay for several popular ADHD drugs, which a USA TODAY analysis found have outpaced inflation – and in some cases doubled or tripled in price – since Adderall fell into short supply starting in October 2022. 1
USA Today - ADHD drug prices rise as Adderall shortage leaves patients scrimping to fill prescriptions
Google it - great for ELTP especially with new partner for XR!
The upward trend can be seen in the prices retail community pharmacies pay for several popular ADHD drugs, which a USA TODAY analysis found have outpaced inflation – and in some cases doubled or tripled in price – since Adderall fell into short supply starting in October 2022. 1
Looks like some need Christmas money... Cannot blame anyone for taking profits as I suspect that many could have a 100% to 400% profit on their investment in ELTP. I expect that most are watching ELTP and will return for another run up!!!
House Oversight Committee investigates FDA over national drug shortage
https://www.washingtonexaminer.com/policy/healthcare/house-oversight-committee-investigates-fda-over-national-drug-shortage
There they go again... 0.127225... six decimal places. Trying to hold ELTP while someone loads up for the next run up. We saw a lot six decimal place trades before the last run up!!!
0.086985 up 0.004985 (6.08%)... WTF is that??? I know it is still up 6% but 0.086985... Why not just 0.087? Why do they take it out six decimal places?
Prasco revenue in the 100s of millions!
$150 million in sales were tracked by an independent consulting company during 2005, reportedly doubling the previous years' figures. link- https://en.wikipedia.org/wiki/Prasco_Laboratories
ST International Inc. - Prasco's annual revenues are $100-$500 million (see exact revenue data) and has 100-500 employees. It is classified as operating in the Drugs & Druggists' Sundries Merchant Wholesalers industry. Link - https://incfact.com/company/stinternationalprasco-mason-oh/
Prasco has partnerships with GlaxoSmithKline, Merck & Co, and MANY, MANY other manufacturers. Their sales and revs are going to be huge.
Prasco entered into agreements with Teva Pharmaceutical Industries Ltd. (Teva) and Shire LLC inn 2016 to acquire the rights to distribute Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate and Amphetamine Sulfate (Mixed Salts of a Single-Entity Amphetamine Product) Extended Release Capsules, CII, 5 mg, 10 mg, 15 mg, 20 mg, 25 mg, and 30 mg, the Authorized Generic (AG) version of Adderall XR® Extended Release Capsules, CII. Which was a huge contributor to Teva revs.
NOW Prasco is partnered with ELITE for generic version of Adderall XR!!! Think about what that means for ELTP revenue!!!
What we know from the ELTP Q1 2024 transcript and the recent news.
Transcript - The Company also submitted partial ANDA for pain management for FDA review. The partial application contained the recently concluded insufflation study. Elite received correspondence from FDA requesting certain information. The information has been gathered and the response will be out to FDA this week. This is one of the three needle mover products that I spoke of six weeks ago.
Elite has another product that is undergoing a pivotal DE clinical trial. If we pass then we expect to file this ANDA this year. Just to make sure that everybody understands me, two of the three needle mover ANDAs as I spoke of will be filed this year.
Now, from the Reuters article on Aug 31, 2023 - The U.S. Food and Drug Administration had said on Monday it has approved generic versions of Vyvanse from 11 drug makers after Takeda's exclusivity over the drug expired on Aug 24.
Now from the ELTP news release - Elite Pharmaceuticals Reports Positive Results From A Pivotal Bioequivalence Study - "The results indicate that the generic product is bioequivalent to the branded product. Elite is compiling the data for this product to file an Abbreviated New Drug Application with the US Food and Drug Administration."
Now, knowing how approvals go, if one of the 11 drug makers has 180 days exclusivity, that will expire by the time ELTP gets approval and launches.
Now, who cares about 180 days? ELTP's generic Adderall IR has a Market Size $335 MILLIOM with 15 competitors and they are pulling in millions! When approved, ELTP's generic versions of Vyvanse will have a Market Size of $5.1 BILLION (again $$BILLION) with 11 competitors (again 11 which is 4 less than generic Adderall)!!! Do the math, if ELTP gets just 1% of the market they will have $51 MILLION or even 5% of the market they will be looking at $255 MILLION.
THIS IS FROM JUST ONE OF THE TWO NEEDLE MOVERS!!!
With Mr. Kirko driving sales and distro, with CURRENT customers of retailers such as CVS, Walgreens, Publix, Myers (which is actually Meijer, transcript error probably), Optisource, Golden Oaks, Red Oaks, and probably more customers signing on, I think ELTP will be closer to the 5% market.
Then we get approval for the second needle mover and add another 5% of $1.16 BILLION!!!
Given we will not see all this potential revenue in 2023 but 2024 will be blast off into the HUNDREDS of MILLIONS in revenue!!! I can wait for that : )
"retailers such as CVS, Walgreens, Publix and Myers" - ELTP has the distribution and customers in place for their undisclosed generic drug product in a class of medications called CNS stimulants. $5.1 billion for the brand and generic market for this product!!!
From the June conference call transcript -
Kirko’s mandate was to develop a commercial sales, marketing and distribution strategy, ecocide and distribution contracts with distributing partners such as McKesson, AmerisourceBergen, Cardinal, buying groups such as Premier Genetics, Optisource, Topco, RX Sourcing strategies, LLC, retailers such as CVS, Walgreens, Publix and Myers.
He also set up the contracting with the Center for Medicare and Medicaid Services CMS to provide access to Elite's products. And was ready for national distribution of 29 NDCs on Elite's label by April 1st, 2023. We got him in September and October, he already signed the contract with Crossroads the 3PL in November, he had the first contract delivered to us with Premier by December. He had contracts with Publix, Myers, Optisource, Golden Oaks and then Red Oaks, which is 50% for our business. He had contracts in place with all of these guys in addition to working with the staff, getting license in all 50 states, listing at in the compendium as well.
ELITE'S FDA Filings
https://fda.report/Company/Elite-Laboratories-Inc
This page includes the latest FDA filings for Elite Laboratories Inc. Currently, you will find the latest 100 filings for Premarket Notifications, Premarket Applications, De Novo Applications, and GUDID registrations.
Device
Company
Device
Date
Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate, and Amphetamine Sulfate
Elite Laboratories, Inc., SunGen Pharma LLC
Prescription Medication
2023-08-19
Acetaminophen and Codeine Phosphate
Elite Laboratories, Inc.
Prescription Medication
2023-05-04
Dantrolene Sodium
Elite Laboratories, Inc.
Prescription Medication
2023-04-20
Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate, and Amphetamine SulfateElite Laboratories, Inc., SunGen Pharma LLC Prescription Medication 2023-01-27
Dantrolene Sodium
Elite Laboratories, Inc.
Prescription Medication
2023-01-07
Trimipramine Maleate
Elite Laboratories, Inc.
Prescription Medication
2023-01-07
Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate
Elite Laboratories, Inc.
Prescription Medication
2022-12-30
Isradipine
Elite Laboratories, Inc., Elite Laboratories, Inc.
Prescription Medication
2022-12-29
NDC 64850-911
Elite Laboratories, Inc.
Isradipine
2022-12-28
NDC 64850-910
Elite Laboratories, Inc.
Isradipine
2022-12-28
Loxapine
Elite Laboratories, Inc.
Prescription Medication
2022-12-23
Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate
Lannett Company, Inc., SunGen Pharma LLC, Elite Laboratories, Inc.
Prescription Medication
2022-09-14
Doxycycline Hyclate
Praxgen Pharmaceuticals LLC, Elite Laboratories, Inc.
rescription Medication
2022-09-01
Vigabatrin
Elite Laboratories, Inc.
Prescription Medication
2022-07-14
NDC 64850-940
Elite Laboratories, Inc.
Vigabatrin
2022-06-24
METHADONE HYDROCHLORIDE
Ascend Laboratories, LLC, Alkem Laboratories
Prescription Medication
2022-06-15
METHADONE HYDROCHLORIDE
Ascend Laboratories, LLC, Alkem Laboratories
Prescription Medication
2022-06-08
Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate
Lannett Company, Inc., SunGen Pharma LLC, Elite Laboratories, Inc.
Prescription Medication
2022-01-15
Loxapine
Burel Pharmaceuticals, Inc., Elite Laboratories, Inc.
Prescription Medication
2021-09-18
Acetaminophen and Codeine Phosphate
Elite Laboratories, Inc., Elite Laboratories, Inc.
Prescription Medication
2021-05-20
Loxapine
Burel Pharmaceuticals, Inc., Elite Laboratories, Inc.
Prescription Medication
2021-05-01
IsradipineEpic Pharma, LLC,
Elite Laboratories, Inc.
Prescription Medication
2021-03-19
Trimipramine Maleate
Epic Pharma, LLC, Elite Laboratories, Inc.
Prescription Medication
2021-03-19
Loxapine
Elite Laboratories, Inc.
Prescription Medication
2020-10-09
Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate, and Amphetamine Sulfate
Lannett Company, Inc., Elite Laboratories, Inc.
Prescription Medication
2020-06-27
Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate
Lannett Company, Inc., SunGen Pharma LLC, Elite Laboratories, Inc.
Prescription Medication
2020-06-27
Isradipine
Glenmark Pharmaceuticals Inc.,USA, Elite Laboratories, Inc., Elite Laboratories, Inc.
Prescription Medication
2020-05-14
Phentermine Hydrochloride
Epic Pharma, LLC, Elite Laboratories, Inc.
Prescription Medication
2020-04-23
NDC 64850-893
Elite Laboratories, Inc.
Loxapine
2020-01-27
NDC 64850-892
Elite Laboratories, Inc.
Loxapine
2020-01-27
NDC 64850-891
Elite Laboratories, Inc.
Loxapine
2020-01-27
NDC 64850-890
Elite Laboratories, Inc.
Loxapine
2020-01-27
Hydromorphone Hydrochloride
Elite Laboratories, Inc.
Prescription Medication
2019-12-28
Ninja...WOW! Elite Pharmaceuticals Inc (ELTP) Stock Surges by 5,417.24%: Analysts Predict Bright Future (this article was a little further down the page on your link).
On August 21, 2023, Elite Pharmaceuticals Inc (ELTP) experienced a significant surge in its stock performance. According to data from CNN Money, the one analyst offering a 12-month price forecast for ELTP has set a median target of $4.00, with both the high and low estimates also at $4.00. This forecast represents a staggering 5,417.24% increase from the last recorded price of $0.07.
The lack of available charts makes it difficult to analyze the stock’s performance in detail. However, the consensus among the one polled investment analyst is to buy ELTP stock. This rating has remained steady since January, indicating a consistent positive outlook for the company.
Elite Pharmaceuticals Inc is a pharmaceutical company that specializes in the development and manufacturing of generic and branded generic products. They focus on controlled-release drug delivery systems and abuse-deterrent technologies. The company’s primary goal is to improve patient outcomes by providing affordable and effective medications.
The optimistic forecast for ELTP stock suggests that investors have confidence in the company’s future prospects. The projected increase of over 5,000% indicates strong growth potential. However, it is important to note that analyst predictions are not always accurate, and stock market fluctuations can be unpredictable.
Investors considering purchasing ELTP stock should conduct thorough research and consider various factors, such as the company’s financial health, competitive landscape, and industry trends. It is also advisable to consult with a financial advisor to make informed investment decisions.
Overall, Elite Pharmaceuticals Inc’s stock performance on August 21, 2023, appears to be highly promising. With analysts predicting a substantial increase in value, the company’s future looks bright. However, investors should exercise caution and conduct their due diligence before making any investment decisions.
Let’s speculate! FDA and DEA are calling on manufacturers to relinquish their remaining 2023 quota allotment since they were short producing about a BILLION doses of Adderall. Let say they do relinquish all or even going low to maybe 10% of their allotment.
We know and it has been stated in ELTP’s report transcripts (go read it for yourself) that ELTP has been able to get API where other manufacturers have struggled. ELTP has met and manufactured their allotment of Adderall which is evident in their continued increasing revenue.
So let say ELTP does pick up some of the relinquished Adderall to help relieve the huge short of the drug.
Full billion relinquished –
1 billion X $0.29 = $290,000,000
10% relinquished – $29,000,000
If ELTP can pick up any of the possible relinquished allotment of Adderall, IT WILL INCREASE ELTP REVENUE!!!
FDA and DEA joint letter regarding Adderall shortage –
https://www.fda.gov/media/170736/download?attachment
Adderall without insurance costs nearly $11 per tablet
https://www.singlecare.com/blog/adderall-without-insurance/
A manufacturer sales generic Adderall for approximately $0.29 based on the cost info below. (Conservative using 20X - $5.81/20=$0.29)
Publicly available data shows Veterans Affairs pays $2.61 a pill for the extended-release version of Adderall from Takeda. The agency pays $5.81 per pill for the immediate-release formula from Teva.
The branded cost is a magnitude higher - 15 to 20 times higher.
https://www.investors.com/news/technology/teva-stock-what-we-know-and-do-not-about-the-adderall-shortage/
We need PROFESSIONAL GOOD GUY HELP that enjoy exposing manipulators and can help us stand up for Elite! Anyone know those that might help???
I am not a professional investor nor am I a social network expert. I am soon to retire general industry guy that will take a chance on a OTC stock every once in a while. I am sure that many of you, like me, get frustrated with those abusing a stock constantly. How do we get the word out and how do we get good guys helping us fight this fight???
Just do a google search - "XXXXX (insert member posting name)" stock message boards and you will see those who are potential bad characters and possibly part of the maneuvers/manipulations TEAM. You can see from their posting history that they specialize in attacking various stocks.
One search found the below... Its an old one but it show how long they are dedicated not having to cover.... its kinda funny actually also.
Guest April 22, 2016, 03:47PM
"Everyone Knows XXXXXX and XXXXXXX on IHUB were hired to bash ELTP by an hedge. Elite next abuse deterrent drug is very very likely to get approved. There really isn't a reason that it won't.
Then there is XXXXXX on IHUB who spent a good 20 years as a ladyboy in a Singapore bar. But was hired to do less honorable work and bash stocks for 10 years.
LOL, google and the web does not forget!
Thoughts on naked short positions in ELTP -
IMO, anyone that thinks there are not bad characters in OTC stocks is delusional. There are those that will work with MMs to hide their maneuvers/manipulations and they both profit from it and most times it works out for them. They thrive on driving suspect companies into bankruptcy and delisting.
What happens when an investor maintains a short position in a company that gets delisted and declares bankruptcy? The answer is simple—the investor never has to pay back anyone because the shares are worthless. https://www.investopedia.com/ask/answers/maintain-short-position-delisted-stock/
I think there are some of these bad characters in ELTP and they thought had a shoe-in for bankruptcy and delisting when SequestOx did not play out. Think about it, they sold short on the way down from the highs of the SquestOx adding a positive balance in the accounts that they could use in other trades and have never had to cover ELTP YET. They did not bank on ELTP surviving and definitely did not see them becoming a profitable company. ELTP continues to grow revenues, increase profit, continue research, and get FDA approvals which will lead to, at some point in the future, BREAKING THE DAMN the bad characters built. When this happens, all shares will have to be accounted for and the shorts or naked shorts will HAVE TO COVER!
We need a GAMESTOP type push for ELTP!!! Anyone have the know-how and the network to get the word out and bring the crowd to ELTP??? I'll be honest - I do not have the social network know-how to bring the attention ELTP needs.
It amazes me that the bad characters in ELTP cannot see the HUGE opportunity to make bank by reversing their agenda, covering positions, and letting ELTP climb back to new heights.
Just thinking out loud and giving my opinion.
How much of 1 billion more doses that they could have produced but did not make or ship will ELTP get???
FDA/DEA re-allocating will be a huge market share increase for ELTP!!!
It is funny reading some of the posts regarding FDA letter regarding Adderall Shortage.
Some are not happy but it does not matter how they try to spin it, it is HUGE news for ELTP!!!
FDA letter regarding Adderall Shortage
August 1, 2023
Dear Americans,
As leaders of the U.S. Food and Drug Administration (FDA) and the Drug Enforcement Administration (DEA), we recognize the important role that prescription stimulants play in the treatment of conditions such as attention-deficit/hyperactivity disorder (ADHD), binge eating disorder, and uncontrollable episodes of deep sleep (narcolepsy). The lack of availability of certain medications in recent months has been understandably frustrating for patients and their families. Given the interest related to access to these medications, we want to provide an update on the ongoing actions being taken to resolve the shortages of prescription stimulant medications. In addition, we want to acknowledge important issues that will need to be addressed through longer-term coordination by a variety of entities involved in this effort. This is not a problem that the FDA and DEA can solve on our own. We are urging all stakeholders to work together to resolve these shortages as quickly as possible. The FDA and DEA do not manufacture drugs and cannot require a pharmaceutical company to make a drug, make more of a drug, or change the distribution of a drug. That said, we are working closely with numerous manufacturers, agencies, and others in the supply chain to understand, prevent, and reduce the impact of these shortages. The current shortage of stimulant medications is the result of many factors. It began last fall due to a manufacturing delay experienced by one drug maker. While this delay has since resolved, we are continuing to experience its effects in combination with record-high prescription rates of stimulant medications. Data show that, from 2012 to 2021, overall dispensing of stimulants (including amphetamine products and other stimulants) increased by 45.5 percent in the United States. According to a U.S. Centers for Disease Control and Prevention report, particularly during 2020-2021, when virtual prescribing was permitted on a widespread basis during the COVID-19 Public Health Emergency, the percentages in certain age groups grew by more than 10 percent. We are calling on key stakeholders, including manufacturers, distributors, pharmacies, and payors, to do all they can to ensure access for patients when a medication is appropriately prescribed. We want to make sure those who need stimulant medications have access. However, it is also an appropriate time to take a closer look at how we can best ensure these drugs are being prescribed thoughtfully and responsibly. Stimulants are controlled substances with a high potential for abuse, which can lead to addiction and overdose. Therefore, there are limits (also known as quotas) set by DEA for how much of these drugs can be produced. However, for amphetamine medications, in 2022, manufacturers did not produce the full amount that these limits permitted them to make. Based on DEA's internal analysis of inventory, manufacturing, and sales data submitted by manufacturers of amphetamine products, manufacturers only sold approximately 70 percent of their allotted quota U.S. Food & Drug Administration 10903 New Hampshire Avenue Silver Spring, MD 20993 www.fda.gov Page 2 for the year, and there were approximately 1 billion more doses that they could have produced but did not make or ship. Data for 2023 so far show a similar trend. We (DEA and the FDA) have called on manufacturers to confirm they are working to increase production to meet their allotted quota amount. If any individual manufacturer does not wish to increase production, we have asked that manufacturer to relinquish their remaining 2023 quota allotment. This would allow DEA to redistribute that allotment to manufacturers that will increase production. DEA is also committed to reviewing and improving our quota process. The FDA is asking professional groups and healthcare providers to accelerate efforts to support appropriate diagnosis and treatment of ADHD, such as further development of additional clinical guidelines for ADHD in adults. In recognition of this need, FDA awarded a grant to the National Academies of Sciences, Engineering, and Medicine (NASEM) to support a scientific meeting on ADHD in adults and considerations for diagnosis and treatment. FDA also recognizes that further research is needed into the diagnosis and treatment of ADHD and believes that research can help inform the development of alternative treatments and an understanding of the behavioral and societal issues leading to widespread misuse of these medications in certain groups. FDA has already taken steps to support the development of alternative treatment options. In 2020, for instance, FDA permitted marketing of a game-based digital therapeutic to improve attention function in children with ADHD. This device offers a non-drug option for improving symptoms associated with ADHD in children. There are also non-stimulant medications approved to treat ADHD, including one approved in 2021. Additionally, to address continuing concerns of misuse, addiction and overdose of prescription stimulants, the FDA recently issued a drug safety communication and required updates to the labeling to standardize prescribing information and clearly inform patients, caregivers and healthcare professionals of these risks. FDA and DEA will continue to do all we can to prevent stimulant drug shortages, limit their impact, and resolve them as quickly as possible. We will consider additional actions to prevent non-medical use and identify efforts to better understand and strengthen the supply chain. We also hope that we can all work together to assure that those who need stimulant medications can get them based on the best clinical knowledge about when they are effective, and avoid them when there is no indication for their use. We will continue to work together and with all of you to mitigate this drug shortage and provide up to date information.
Sincerely,
Robert M. Califf, M.D.
Commissioner of Food and Drugs
U.S. Food and Drug Administration
Anne M. Milgram
Administrator Drug Enforcement Administration
Bloomberg - Adderall Shortage Has US Agencies Urging Drugmakers to Boost Output
GOOD NEWS FOR ELTP!!!
Link to FDA letter - https://www.fda.gov/media/170736/download?attachment
Is ELTP positioning for a deal?